Efficacy of methotrexate in pediatric Crohn's disease: A French multicenter study

Inflammatory Bowel Diseases

Volumn 12, Issue 11, 2006, Pages 1053-1057

  Uhlen, S ^a   Belbouab, R ^b   Narebski, K ^c   Goulet, O ^c,d,e   Schmitz, J ^c,d,e   Cezard J P ^b,f   Turck, D ^a   Ruemmele, F M ^c,d,e  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UPRES EA 1833   (France)

Author keywords

Crohn's disease; Methotrexate; Pediatric

Indexed keywords

ANTIEMETIC AGENT; AZATHIOPRINE; CORTICOSTEROID; FOLIC ACID; LIVER ENZYME; METHOTREXATE; PREDNISOLONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; ASTHENIA; CONTROLLED STUDY; CROHN DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PEDIATRICS; PRIORITY JOURNAL; RELAPSE; REMISSION; SCHOOL CHILD; SIDE EFFECT; TREATMENT INDICATION; TREATMENT WITHDRAWAL; VOMITING;

AZATHIOPRINE; CHILD; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33750519460     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.mib.0000235103.47280.bb     Document Type: Article

References (22)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429.
2. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533.
3. Doering J, Begue B, Lentze MJ, et al. Induction of T-lymphocyte apoptosis by sulfasalazine in patients with Crohn's disease. Gut. 2004;11:1632-1638.
4. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+T lymphocytes. J Clin Invest. 2003;111:1133-1145.
5. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145-1157.
6. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000;2:CD2000067.
7. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercatpropurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000;2:CD000545.
8. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902.
9. Ward MM. Trends in the use of disease modifying antirheumatic medications in rheumatoid arthritis, 1980-1995: results from the National Ambulatory Medical Care Surveys. J Rheumatol. 1999;26:546-550.
10. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;110:353-356.
11. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease: the North American Crohn's Study Group Investigators. N Engl J Med. 1995;332:292-297.
12. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease: North American Crohn's Study Group Investigators. N Engl J Med. 2000;342:1627-1632.
13. Lemann M, Zenjari T, Bouhnik Y, Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol. 2000;95:1730-1734.
14. Mack DR, Young R, Kaufman SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr. 1998;132:830-835.
15. Gower-Rousseau C, Salomez C, Dupas JL, et al. Incidence of inflammatory bowel disease in northern France (1988-1990). Gut. 1994;35:1433-1438.
16. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
17. Kremer JM, Alarcn GS, Lightfoot RW, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity: American College of Rheumatology. Arthritis Reum. 1994;37:316-328.
18. Soon SY, Ansari A, Yaneza M, et al. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2004;16:921-926.
19. Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998;102:322-328.
20. Lemann M, Mary JY, Colombel JF, et al, for GETAID. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128:1812-1818.
21. Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996;347:215-219.
22. Vandell AG, DiPiro JT. Low-dosage methotrexate for treatment and maintenance of remission in patients with inflammatory bowel disease. Pharmacotherapy. 2002;22:613-620.